Developer docs
API playgroundTry for free, no card

Search company profiles

Matica Biotechnology

Full company profile

uuid00049lr

Namestring
Matica Biotechnology
Legal namestring
Matica Biotechnology, Inc.
Websiteurl
maticabio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) headquartered in College Station, Texas, founded in 2019 and operating as a U.S. subsidiary of South Korean conglomerate CHA Biotech. The company provides end-to-end CDMO services spanning cell line and vector development, upstream and downstream process development, assay development, GMP production, and quality services for advanced therapy developers, academic medical centers, and pharmaceutical companies. Its proprietary technology stack centers on the MatiMax™ cell line platform, in-line process monitoring, and single-use manufacturing systems, delivered from a purpose-built cGMP facility and supported by a network of five Matica sites worldwide.

The company's commercial model is fee-for-service / professional services, with project-based contracts for GMP manufacturing, process and analytical development, and regulatory support (IND and BLA filings). It has disclosed >300 viral vector projects, >36 cell therapy projects, >20 IND filings prepared, and 5 BLA project filings managed. In June 2026, Matica launched two new platform offerings: the Open Access Platform for AAV, which provides flexible, non-exclusive manufacturing pathways with retained client IP (anchored by Cirsium Biosciences), and the Korea IIT Integrated Platform, which combines Korean clinical trial infrastructure with U.S.-based manufacturing for investigator-initiated trials. The company is led by CEO Paul H. Kim (appointed October 2024, 30+ years of CDMO/CRO/biotech experience) and CCO Min Park (25+ years, formerly CBO at WuXi Advanced Therapies, Catalent, Samsung Biologics, Abzena, and DSM), with technical leadership drawn from Genentech, Amgen, Fujifilm Diosynth, and Boehringer-Ingelheim.

Short descriptiontext

Matica Biotechnology is a viral vector and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services to biotech, pharma, and academic developers from its purpose-built Texas facility and five global sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCollege Station, United States
HQ citystring
College Station
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, gene therapy CDMO, cell therapy development, contract manufacturing services, GMP production services
Industry4 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Manufacturing (Viral Vector CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Matica Bio provides fee-for-service CDMO manufacturing services including cell line development, process development, assay development, GMP production, and quality services. Revenue is generated through project-based contracts with biotech and pharma clients for viral vector manufacturing across clinical and commercial stages.

maticabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1MatiMax™ Platform
Description

Proprietary cell line platform for advanced therapy manufacturing

maticabio.com
+2 more records
Core offering1 text field

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing services from cell line and process development through cGMP production and quality release. Its offering is delivered at a purpose-built cGMP facility in College Station, Texas, leveraging proprietary MatiMax™ cell lines, in-line process monitoring, and single-use technologies, and is extended globally through an integrated Korea–U.S. platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >20 IND filings prepared for clients
+3 more records
Product overview1 text field

Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of advanced therapy manufacturing services. The company's portfolio includes the MatiMax™ proprietary cell line platform for enhanced production, the Open Access Platform for AAV providing flexible non-exclusive manufacturing pathways, and an integrated Korea IIT Platform Solution combining Korean clinical trial infrastructure with U.S. manufacturing. Core services span cell line and vector development, process development, assay development, GMP production, and quality services—all delivered through purpose-built cGMP facilities utilizing advanced technologies, in-line process monitoring, and single-use systems across five Matica sites worldwide.

Product and service9 records
1MatiMax™ Platform
CategoryManufacturing Platform / Proprietary Cell Line Technology
Description

Proprietary cell line platform developed by Matica Biotechnology for enhanced viral vector and gene therapy manufacturing, representing the company's core proprietary technology for cell-based production.

2Open Access Platform for AAV
CategoryManufacturing Platform / AAV CDMO Engagement Model
Description

Open-access manufacturing platform providing flexible, non-exclusive AAV manufacturing pathways with transparent process development, data access, and accelerated scalability from early development to commercial readiness, designed for gene therapy innovators.

3Cell and Gene Therapy Development and Manufacturing Services
CategoryCDMO Service / End-to-End Advanced Therapy Manufacturing
Description

End-to-end solution for advanced therapy manufacturing spanning the entire product lifecycle from development through commercialization, integrating clinical execution with GMP manufacturing, process development, analytical development, and regulatory support for biotech, pharma, and academic clients.

4Cell Line and Vector Development
CategoryCDMO Service / Cell Line and Vector Development
Description

Development and production of cell lines and viral vectors for gene therapy applications, including proprietary MatiMax™ cell lines and various viral vector platforms, provided to biotech, pharma, and academic clients.

5Process Development
CategoryCDMO Service / Process Development
Description

Upstream and downstream process development services for viral vector manufacturing, including upstream process development, downstream process development, and process engineering delivered to advanced therapy developers.

6Assay Development
CategoryCDMO Service / Analytical Assay Development
Description

Analytical method development and validation services for characterizing viral vectors, including methods for wild-type and recombinant viruses across all biosafety levels (BSL1–BSL4), provided to gene therapy and cell therapy developers.

7GMP Production
CategoryCDMO Service / cGMP Manufacturing
Description

cGMP manufacturing services for viral vectors and gene therapies performed at the company's purpose-built cGMP facility in College Station, Texas, utilizing advanced technologies and single-use systems for advanced therapy clients.

8Quality Services
CategoryCDMO Service / Quality Control and Quality Services
Description

Quality control testing and quality services supporting process development, GMP manufacturing, and product release for advanced therapy manufacturing, serving gene therapy and cell therapy clients.

9Korea IIT Integrated Platform Solution
CategoryIntegrated Platform / Clinical-Manufacturing Solution
Description

Integrated platform solution combining Korean clinical trial infrastructure with U.S.-based manufacturing capabilities, designed to accelerate investigator-initiated trials (IITs) and early translational development for global cell and gene therapy programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Matica Bio and Cirsium Biosciences announced adoption of the Matica Open Access Platform for AAV manufacturing. The partnership integrates Cirsium's plant-based AAV technology with Matica Bio's downstream and analytical expertise, providing flexible, transparent, and scalable gene therapy manufacturing under an open-access model.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Matica Bio engaged by UHN's Toronto General Hospital to supply cGMP manufacturing of IL-10 adenoviral gene therapy designed for delivery to donor lungs during ex vivo lung perfusion prior to transplantation. Services include research cell bank generation, adenovirus seed synthesis, process development, analytical development, testing, and cGMP manufacturing.

3Major North American Research Institution
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Matica Bio signed a CDMO contract with a major North American research institution for adenovirus therapeutics development covering stages from process development to cGMP manufacturing.

koreabiomed.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Strategic partnership to support IND submission for Calidi's oncolytic virus therapy CLD-401 targeting metastatic tumors. Matica Bio provides analytical, process development, and GMP manufacturing services at its Texas facility for Calidi's cancer immunotherapy program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-10
Description

Strategic partnership for viral vector and cell therapy production, combining Matica Bio's viral vector manufacturing capabilities with CytoImmune's cell therapy development expertise.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CDMO partnership for viral vector development and manufacturing services supporting KaliVir's immunotherapy programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership to accelerate TCR-T cell therapy development, combining manufacturing and development expertise.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership to advance innovative therapies for pediatric brain tumors through manufacturing collaboration.

9Child's Cure Genetic Research
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to drive innovation in pediatric rare disease therapies through manufacturing support.

maticabio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to deliver end-to-end support for cell and gene therapy innovators, combining Texas A&M's research capabilities with Matica Bio's manufacturing expertise.

Strategic tierCoreTypeTechnology or Integration
Description

Joint research agreement for the development of advanced viral vector manufacturing technology, combining process development expertise.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Australian CRO Avance Clinical to provide clinical trial initiation services for Calidi Biotherapeutics programs.

Strategic tierCoreTypeOthers
Description

Matica Biotechnology is the U.S. subsidiary of CHA Biotech, part of CHA Medical & Bio Group. CHA Biotech provides strategic support and access to the broader CHA network including Korea-based clinical infrastructure.

Strategic tierMinorTypeOthers
Description

Paul Kim, CEO of Matica Bio, serves on the board of SCAI Therapeutics.

Strategic tierMinorTypeOthers
Description

Paul Kim, CEO of Matica Bio, serves on the board of Riva Therapeutics in San Diego.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gene therapy-focused CDMO offering AAV manufacturing, process development, and related services. Directly comparable in target market (gene therapy developers), service scope, and growth stage.

TypeRegional player
Description

South Korea-based large-scale CDMO that is also relevant as an Asian regional peer given CHA Biotech's Korean roots. Min Park previously served as CBO at Samsung Biologics, indicating direct experience with this competitor.

TypeBroad incumbent
Description

Large-scale global CDMO with significant viral vector and gene therapy manufacturing capabilities (e.g., Paragon Bioservices acquisition). Matica's CCO Min Park previously served as CBO at Catalent, indicating direct personnel and competitive overlap.

TypeOthers
Description

Bioprocessing equipment and integrated solutions provider with a strategic joint research agreement with Matica for advanced viral vector manufacturing technology. Comparable as an ecosystem/technology partner rather than direct competitor.

5Yposkesi
TypeDirect peer
Description

European viral vector and gene therapy CDMO offering AAV and lentiviral manufacturing for clinical and commercial stages. Direct competitor in the specialty gene therapy CDMO segment.

TypeDirect peer
Description

Specialty viral vector CDMO focused on AAV and other gene therapy vectors for clinical and commercial supply. Closest comparable peer to Matica in terms of scale, service offering, and target customer base.

TypeBroad incumbent
Description

One of the largest global CDMOs with established viral vector and cell therapy manufacturing capacity. Competes for similar gene therapy development and manufacturing contracts across clinical and commercial stages.

TypeBroad incumbent
Description

Major CDMO with viral vector and gene therapy manufacturing offerings. Multiple Matica senior leaders (Milton Pollard, Daniel Mitchell, Trent Lyman, Sarah Link) came from Fujifilm Diosynth, reflecting deep technical and competitive overlap.

9VGXI (Genezen)
TypeDirect peer
Description

Viral vector CDMO providing plasmid DNA, AAV, lentivirus, and other gene therapy manufacturing services. Closely comparable specialty CDMO competing for similar gene therapy development clients.

TypeBroad incumbent
Description

Global CDMO with dedicated gene and cell therapy manufacturing capabilities through WuXi Advanced Therapies unit. Min Park previously served as CBO there. Comparable full-spectrum gene therapy CDMO offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Matica Biotechnology

Biopharmaceutical Contract Manufacturing (Viral Vector CDMO)maticabio.com

Matica Biotechnology is a viral vector and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services to biotech, pharma, and academic developers from its purpose-built Texas facility and five global sites.

What Matica Biotechnology does

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) headquartered in College Station, Texas, founded in 2019 and operating as a U.S. subsidiary of South Korean conglomerate CHA Biotech. The company provides end-to-end CDMO services spanning cell line and vector development, upstream and downstream process development, assay development, GMP production, and quality services for advanced therapy developers, academic medical centers, and pharmaceutical companies. Its proprietary technology stack centers on the MatiMax™ cell line platform, in-line process monitoring, and single-use manufacturing systems, delivered from a purpose-built cGMP facility and supported by a network of five Matica sites worldwide.

The company's commercial model is fee-for-service / professional services, with project-based contracts for GMP manufacturing, process and analytical development, and regulatory support (IND and BLA filings). It has disclosed >300 viral vector projects, >36 cell therapy projects, >20 IND filings prepared, and 5 BLA project filings managed. In June 2026, Matica launched two new platform offerings: the Open Access Platform for AAV, which provides flexible, non-exclusive manufacturing pathways with retained client IP (anchored by Cirsium Biosciences), and the Korea IIT Integrated Platform, which combines Korean clinical trial infrastructure with U.S.-based manufacturing for investigator-initiated trials. The company is led by CEO Paul H. Kim (appointed October 2024, 30+ years of CDMO/CRO/biotech experience) and CCO Min Park (25+ years, formerly CBO at WuXi Advanced Therapies, Catalent, Samsung Biologics, Abzena, and DSM), with technical leadership drawn from Genentech, Amgen, Fujifilm Diosynth, and Boehringer-Ingelheim.

Matica Biotechnology firmographics

Firmographics
Name
Matica Biotechnology
Legal name
Matica Biotechnology, Inc.
Website
https://maticabio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Matica Biotechnology is a viral vector and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services to biotech, pharma, and academic developers from its purpose-built Texas facility and five global sites.
Ownership category
akta.pro rank

Matica Biotechnology industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (Viral Vector CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Viral vector manufacturing
  • Gene therapy CDMO
  • Cell therapy development
  • Contract manufacturing services
  • GMP production services

Where Matica Biotechnology is headquartered

Location

Headquarters

HQ city
College Station
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Matica Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Contract Manufacturing Services: Matica Bio provides fee-for-service CDMO manufacturing services including cell line development, process development, assay development, GMP production, and quality services. Revenue is generated through project-based contracts with biotech and pharma clients for viral vector manufacturing across clinical and commercial stages.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Matica Biotechnology product offering

Product offering

Core offering

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing services from cell line and process development through cGMP production and quality release. Its offering is delivered at a purpose-built cGMP facility in College Station, Texas, leveraging proprietary MatiMax™ cell lines, in-line process monitoring, and single-use technologies, and is extended globally through an integrated Korea–U.S. platform.

Product overview

Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of advanced therapy manufacturing services. The company's portfolio includes the MatiMax™ proprietary cell line platform for enhanced production, the Open Access Platform for AAV providing flexible non-exclusive manufacturing pathways, and an integrated Korea IIT Platform Solution combining Korean clinical trial infrastructure with U.S. manufacturing. Core services span cell line and vector development, process development, assay development, GMP production, and quality services—all delivered through purpose-built cGMP facilities utilizing advanced technologies, in-line process monitoring, and single-use systems across five Matica sites worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • MatiMax™ Platform: Proprietary cell line platform for advanced therapy manufacturing
  • Open Access Platform
  • Accelerated Matica Korea IIT Integrated Platform Solution

Products and services

  • MatiMax™ Platform Proprietary cell line platform developed by Matica Biotechnology for enhanced viral vector and gene therapy manufacturing, representing the company's core proprietary technology for cell-based production.
  • Open Access Platform for AAV Open-access manufacturing platform providing flexible, non-exclusive AAV manufacturing pathways with transparent process development, data access, and accelerated scalability from early development to commercial readiness, designed for gene therapy innovators.
  • Cell and Gene Therapy Development and Manufacturing Services End-to-end solution for advanced therapy manufacturing spanning the entire product lifecycle from development through commercialization, integrating clinical execution with GMP manufacturing, process development, analytical development, and regulatory support for biotech, pharma, and academic clients.
  • Cell Line and Vector Development Development and production of cell lines and viral vectors for gene therapy applications, including proprietary MatiMax™ cell lines and various viral vector platforms, provided to biotech, pharma, and academic clients.
  • Process Development Upstream and downstream process development services for viral vector manufacturing, including upstream process development, downstream process development, and process engineering delivered to advanced therapy developers.
  • Assay Development Analytical method development and validation services for characterizing viral vectors, including methods for wild-type and recombinant viruses across all biosafety levels (BSL1–BSL4), provided to gene therapy and cell therapy developers.
  • GMP Production cGMP manufacturing services for viral vectors and gene therapies performed at the company's purpose-built cGMP facility in College Station, Texas, utilizing advanced technologies and single-use systems for advanced therapy clients.
  • Quality Services Quality control testing and quality services supporting process development, GMP manufacturing, and product release for advanced therapy manufacturing, serving gene therapy and cell therapy clients.
  • Korea IIT Integrated Platform Solution Integrated platform solution combining Korean clinical trial infrastructure with U.S.-based manufacturing capabilities, designed to accelerate investigator-initiated trials (IITs) and early translational development for global cell and gene therapy programs.

Quantifiable outcome

  • >20 IND filings prepared for clients
  • +3 more outcomes

Companies that use Matica Biotechnology

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Matica Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Matica Biotechnology partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Cirsium BiosciencescoreStrategic or Co-development Partner · 16 June 2026Matica Bio and Cirsium Biosciences announced adoption of the Matica Open Access Platform for AAV manufacturing. The partnership integrates Cirsium's plant-based AAV technology with Matica Bio's downstream and analytical expertise, providing flexible, transparent, and scalable gene therapy manufacturing under an open-access model.
  • University Health Network (UHN)coreStrategic or Co-development Partner · 9 June 2026Matica Bio engaged by UHN's Toronto General Hospital to supply cGMP manufacturing of IL-10 adenoviral gene therapy designed for delivery to donor lungs during ex vivo lung perfusion prior to transplantation. Services include research cell bank generation, adenovirus seed synthesis, process development, analytical development, testing, and cGMP manufacturing.
  • Major North American Research InstitutioncoreStrategic or Co-development Partner · 26 March 2026Matica Bio signed a CDMO contract with a major North American research institution for adenovirus therapeutics development covering stages from process development to cGMP manufacturing.
  • Calidi BiotherapeuticscoreStrategic or Co-development Partner · 3 November 2025Strategic partnership to support IND submission for Calidi's oncolytic virus therapy CLD-401 targeting metastatic tumors. Matica Bio provides analytical, process development, and GMP manufacturing services at its Texas facility for Calidi's cancer immunotherapy program.
  • CytoImmune TherapeuticscoreStrategic or Co-development Partner · 10 October 2024Strategic partnership for viral vector and cell therapy production, combining Matica Bio's viral vector manufacturing capabilities with CytoImmune's cell therapy development expertise.
  • KaliVir ImmunotherapeuticsminorStrategic or Co-development PartnerCDMO partnership for viral vector development and manufacturing services supporting KaliVir's immunotherapy programs.
  • Mongoose BiominorStrategic or Co-development PartnerStrategic partnership to accelerate TCR-T cell therapy development, combining manufacturing and development expertise.
  • TreovirminorStrategic or Co-development PartnerStrategic partnership to advance innovative therapies for pediatric brain tumors through manufacturing collaboration.
  • Child's Cure Genetic ResearchminorStrategic or Co-development PartnerCollaboration to drive innovation in pediatric rare disease therapies through manufacturing support.
  • Texas A&M National Cell Therapy Institute (NCTM)coreStrategic or Co-development PartnerStrategic partnership to deliver end-to-end support for cell and gene therapy innovators, combining Texas A&M's research capabilities with Matica Bio's manufacturing expertise.
  • SartoriuscoreTechnology or IntegrationJoint research agreement for the development of advanced viral vector manufacturing technology, combining process development expertise.
  • Avance ClinicalminorChannel Partner/ Reseller/ DistributorPartnership with Australian CRO Avance Clinical to provide clinical trial initiation services for Calidi Biotherapeutics programs.
  • CHA Biotech (Parent Company)coreOthersMatica Biotechnology is the U.S. subsidiary of CHA Biotech, part of CHA Medical & Bio Group. CHA Biotech provides strategic support and access to the broader CHA network including Korea-based clinical infrastructure.
  • SCAI TherapeuticsminorOthersPaul Kim, CEO of Matica Bio, serves on the board of SCAI Therapeutics.
  • Riva TherapeuticsminorOthersPaul Kim, CEO of Matica Bio, serves on the board of Riva Therapeutics in San Diego.

Scale indicators6 records

Recent moves10 records

Expansion highlights7 records

Matica Biotechnology competitors and assessment

Company assessment

Direct peers

  • Forge Biologics: Gene therapy-focused CDMO offering AAV manufacturing, process development, and related services. Directly comparable in target market (gene therapy developers), service scope, and growth stage.
  • Yposkesi: European viral vector and gene therapy CDMO offering AAV and lentiviral manufacturing for clinical and commercial stages. Direct competitor in the specialty gene therapy CDMO segment.
  • Andelyn Biosciences: Specialty viral vector CDMO focused on AAV and other gene therapy vectors for clinical and commercial supply. Closest comparable peer to Matica in terms of scale, service offering, and target customer base.
  • VGXI (Genezen): Viral vector CDMO providing plasmid DNA, AAV, lentivirus, and other gene therapy manufacturing services. Closely comparable specialty CDMO competing for similar gene therapy development clients.

Regional players

  • Samsung Biologics: South Korea-based large-scale CDMO that is also relevant as an Asian regional peer given CHA Biotech's Korean roots. Min Park previously served as CBO at Samsung Biologics, indicating direct experience with this competitor.

Broad incumbents

  • Catalent: Large-scale global CDMO with significant viral vector and gene therapy manufacturing capabilities (e.g., Paragon Bioservices acquisition). Matica's CCO Min Park previously served as CBO at Catalent, indicating direct personnel and competitive overlap.
  • Lonza: One of the largest global CDMOs with established viral vector and cell therapy manufacturing capacity. Competes for similar gene therapy development and manufacturing contracts across clinical and commercial stages.
  • Fujifilm Diosynth Biotechnologies: Major CDMO with viral vector and gene therapy manufacturing offerings. Multiple Matica senior leaders (Milton Pollard, Daniel Mitchell, Trent Lyman, Sarah Link) came from Fujifilm Diosynth, reflecting deep technical and competitive overlap.
  • WuXi AppTec (WuXi Advanced Therapies): Global CDMO with dedicated gene and cell therapy manufacturing capabilities through WuXi Advanced Therapies unit. Min Park previously served as CBO there. Comparable full-spectrum gene therapy CDMO offering.

Others

  • Sartorius: Bioprocessing equipment and integrated solutions provider with a strategic joint research agreement with Matica for advanced viral vector manufacturing technology. Comparable as an ecosystem/technology partner rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Matica Biotechnology social profiles

Digital presence

Matica Biotechnology compliance and trust

Trust signal

Compliance5 records

Matica Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Matica Biotechnology leadership team

Management profile

Number of profiles

Profiles6 records

Matica Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Matica Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matica Biotechnology

What does Matica Biotechnology do?

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing services from cell line and process development through cGMP production and quality release. Its offering is delivered at a purpose-built cGMP facility in College Station, Texas, leveraging proprietary MatiMax™ cell lines, in-line process monitoring, and single-use technologies, and is extended globally through an integrated Korea–U.S. platform.

Is Matica Biotechnology a public or private company?

Matica Biotechnology is a private company. It is classified as corporate owned and is currently operating.

When was Matica Biotechnology founded?

Matica Biotechnology was founded in 2019. It employs 51 to 100 people.

Where is Matica Biotechnology based?

Matica Biotechnology is headquartered in College Station, United States, in the North America region.

How does Matica Biotechnology make money?

One revenue line is on record: contract Manufacturing Services.

Who are Matica Biotechnology's main competitors?

Direct peers on record are Forge Biologics, Yposkesi, Andelyn Biosciences and VGXI (Genezen). Samsung Biologics is listed as a regional player. Broad incumbents are Catalent, Lonza, Fujifilm Diosynth Biotechnologies and WuXi AppTec (WuXi Advanced Therapies). Sartorius is listed as an others.

Does Matica Biotechnology have an API?

No public API is recorded for Matica Biotechnology.

What industry is Matica Biotechnology in?

Matica Biotechnology's product category is Biopharmaceutical Contract Manufacturing (Viral Vector CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldMatica Bio joins hands with Bondwell for protein productionMatica Bio, a US subsidiary of Cha Biotech, partnered with Texas-based Bondwell Technologies to accelerate development of protein-based materials. Matica Bio will provide process optimization services, leveraging its cell and gene therapy experience. The collaboration aims to bring Bondwell's biomaterials to market sooner and expand Matica Bio's process development capabilities.PR NewswireMatica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech InnovationMatica Biotechnology and Bondwell Technologies announced a collaboration to advance Texas biotech innovation. Matica Bio will provide development expertise to help Bondwell's manufacturing readiness and support commercialization. The partnership aims to strengthen Texas's biotechnology infrastructure and accelerate next-generation life science technologies.The Korea HeraldMatica Bio zeroes in on bridging global biotech with KoreaMatica Biotechnology, the US-based subsidiary of Korea's Cha Biotech, is hosting an online seminar to position South Korea as a strategic destination for investigator-initiated trials (IITs) amid global drugmakers diversifying manufacturing and clinical development away from China. The company launched an integrated platform in June that provides overseas biotechnology firms a single point of contact for conducting IITs in Korea, combining US manufacturing capabilities with Korean clinical expertise, hospital networks, and regulatory support. The platform aims to reduce project management burdens, shorten development timelines, and improve efficiency by streamlining coordination between Matica's US GMP facility and clinical execution in Korea.The Korea HeraldMatica Bio, VaxDome partner on antiviral hybrid vaccine developmentMatica Biotechnology, a US contract development and manufacturing organization subsidiary of CHA Biotech, has partnered with VaxDome Inc. to jointly develop an antigen-agnostic antiviral vaccine designed to protect against a broad range of infectious diseases. Under the agreement, Matica Biotechnology will provide process development, analytical development, and production of non-GMP and cGMP materials to advance VaxDome's hybrid vaccine candidates into clinical trials. The partnership leverages Matica Bio's viral vector manufacturing expertise and single-use technologies at its Texas facility to support the candidate's progression from early development through clinical-scale production.BioSpaceMatica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease ModelsMatica Bio and VaxDome are partnering to develop antigen-agnostic antiviral-vaccine hybrid candidates, with influenza as a disease model. Matica Bio will provide process development, analytical development, and production of clinical materials at its Texas facility. The collaboration aims to bring the candidates into clinical trials.PR NewswireMatica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease ModelsMatica Bio and VaxDome are partnering to bring antigen-agnostic antiviral-vaccine hybrid candidates into clinical trials, with Matica Bio providing process, analytical, and production services. The project centers on VaxDome's zIFV platform, which transforms influenza virus strains into intranasal hybrids for broad viral and lung cancer protection. Matica Bio will manage the technical transition to clinical production.BioSpaceMatica Biotechnology Launches Integrated Korea IIT Platform Solution to Accelerate Global Advanced Therapy DevelopmentMatica Biotechnology announced the launch of an integrated Korea IIT platform solution designed to accelerate investigator initiated trials and early translational development for global cell and gene therapy developers. The platform combines Korean clinical execution capabilities with Matica Bio's U.S.-based manufacturing, process development, and regulatory expertise, positioning Korea as a strategic hub for advanced therapy development. The initiative reflects growing global demand for efficient clinical development pathways as sponsors increasingly seek alternatives to fragmented, multi-vendor approaches.PR NewswireMatica Biotechnology Launches Integrated Korea IIT Platform Solution to Accelerate Global Advanced Therapy DevelopmentMatica Biotechnology has launched an integrated platform solution combining Korean clinical trial infrastructure with its U.S.-based manufacturing capabilities to accelerate investigator initiated trials and early translational development for global cell and gene therapy programs. The platform leverages Korea's established GCP infrastructure, experienced principal investigators, and regulatory alignment with FDA, EMA, and PMDA, positioning the country as an emerging hub for advanced therapy development. This initiative enables biotech innovators to reduce operational complexity by connecting clinical execution with GMP manufacturing, process development, and regulatory support within a single collaborative framework.The Korea HeraldMatica Biotechnology launches open-access manufacturing platformMatica Biotechnology, the US subsidiary of CHA Biotech, launched its Matica Open Access Platform with Cirsium Biosciences as the first customer, offering drug developers greater control over manufacturing with retained IP ownership and eliminated cell-line milestone payments and royalty fees. The platform challenges the traditional contract development and manufacturing organization model and expands an existing partnership focused on AAV vector development and manufacturing for gene therapies. The companies plan to showcase the platform at the BIO International Convention 2026 in San Diego.